- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lubiprostone effective in patients with NAFLD with constipation: Study
According to the latest study, Lubiprostone was well tolerated in non-alcoholic fatty liver disease patients with constipation. It also reduced the liver enzymes in them. The recent study was published in the journal, "The Lancet Gastroenterology & Hepatology" 2020.
Lubiprostone is a bicyclic fatty acid compound derived from a metabolite of prostaglandin E1. It is a laxative drug that improves intestinal permeability. Non-alcoholic fatty liver disease comprises deposition of adipose tissue in the liver leading to progressive steatosis, hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Researchers from Japan conducted a study to assess the efficacy and safety of lubiprostone in patients with non-alcoholic fatty liver disease (NAFLD) with constipation via attenuation of intestinal permeability.
Also Read:Also Read:Vitamin D supplementation in infants alters gut microbiome composition: Study
The study was conducted in Yokohama City University Hospital, Japan between March 24, 2017, and April 3, 2018. The study was a randomized, double-blind, placebo-controlled, phase 2a trial. Patients aged 20-85 years with non-alcoholic fatty liver disease and constipation and having alanine aminotransferase (ALT) at least 40 U/L, liver stiffness (≤6·7 kPa), and a hepatic fat fraction of at least 5·2% (as assessed by MRI-proton density fat fraction) were taken into the study. The randomisation of eligible patients was done by a computer-generated system. After stratification by age and sex, the participants received 24 μg lubiprostone, 12 μg lubiprostone, or placebo, orally, once per day for 12 weeks. The primary endpoint was the absolute changes in ALT at 12 weeks. Efficacy analysis was done by intention to treat and safety was assessed in all treated patients.
The key findings of the study were:
• Out of 288 patients, 150 were randomly assigned to treatment.
• 55 patients were assigned to receive 24 μg lubiprostone, 50 to receive 12 μg lubiprostone, and 45 to receive a placebo.
• A greater decrease in the absolute ALT levels from baseline to 12 weeks was seen in the 24 μg lubiprostone group than in the placebo group and in the 12 μg lubiprostone group than in the placebo group.
• 18 (33%) of 55 patients in the 24 μg group had at least one adverse event, as did three (6%) of 47 patients in the 12 μg group and three (7%) of 43 in the placebo group.
• The most common adverse event was diarrhea seen in 17 [31%] of patients in the 24 μg group, three [6%] in the 12 μg group, and none in the placebo group.
• No life-threatening events or treatment-related deaths occurred.
Thus, the researchers concluded that Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients with NAFLD and constipation. They also suggested Further studies to better define the efficacy and tolerability of lubiprostone in patients with NAFLD without constipation.
For further reading, click the following link: https://doi.org/10.1016/S2468-1253(20)30216-8
BDS, MDS
Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751